Application of liquid biopsy genotyping in lung cancer | LCTT
During the last decade, several tumor molecular alterations have been identified as drivers of cancer proliferation and survival, leading to the development of novel specific targeted agents for different tumors,...
Conclusions: In this article, we present a review of the currently available data about the utility and application of liquid biopsy in lung cancer, with a particular focus on the approach to different techniques of analysis for liquid biopsy and a comparison with tissue samples as well as the potential practical uses in early and...
-
Advances in RET Therapy2yrKey Points • Source: Lung Cancer: Targets and Therapy • Conclusions/Relevance: “Liquid biopsy may represent a less invasive and more feasible alternative to tissue biopsy in many cancer settings, from a promising detection method Show More
Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis
Source : https://www.frontiersin.org/articles/10.3389/fphar.2023.1064227/full
Background and purpose: Although immune checkpoint inhibitors (ICIs) have become the first-line treatment for metastatic non-small cell lung cancer (mNSCLC), their efficacy is limited. Meanwhile, recent reports suggest that radiotherapy...
Conclusions: In this article, we present a review of the currently available data about the utility and application of liquid biopsy in lung cancer, with a particular focus on the approach to different techniques of analysis for liquid biopsy and a comparison with tissue samples as well as the potential practical uses in early and...
Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal - PharmacoEconomics
Source : https://link.springer.com/article/10.1007/s40273-023-01247-w
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Roche) of pralsetinib (Gavreto®), as part of the single technology appraisal (STA) process, to submit evidence for the...
Conclusions: Relevance: Although the clinical evidence suggested that pralsetinib could be clinically effective, National Institute for Health and Care Excellence (NICE) did not recommend pralsetinib within its marketing authorization for treating rearranged during transfection (RET) fusion-positive advanced non-small-cell lung cancer (NSCLC) in...
Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
Source : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0277708
Obesity and sarcopenia have been reported to affect outcomes in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). We analyzed prospective data from 52 patients...
/>
Conclusions: In this study we demonstrated that reduced subcutaneous adiposity and skeletal muscle depletion could possibly constitute negative prognostic factors for individuals with metastatic NSCLC treated with ICIs. In our cohort, low SFI values (either as a continuous variable or as a categorical variable) were significantly associated...
Immune checkpoint inhibitors for RET fusion non-small cell... : Anti-Cancer Drugs
e (RET) gene fusion was identified in 1-2% of NSCLC patients. More recently, two selective RET inhibitors, selpercatinib and pralsetinib, demonstrated higher efficacy and good tolerability. In contrast, the activity...
Conclusions: More recently, two selective RET inhibitors, selpercatinib and pralsetinib, demonstrated higher efficacy and good tolerability. In contrast, the activity of ICIs in RET fusion NSCLC has not been well characterized. Here, we analyzed the clinical data of ICIs and discussed the suitable time to introduce ICIs in RET fusion NSCLC....